MX2024010899A - Formulación acuosa estable de un anticuerpo anti-adrenomedulina (adm) o fragmento de anticuerpo anti-adm. - Google Patents
Formulación acuosa estable de un anticuerpo anti-adrenomedulina (adm) o fragmento de anticuerpo anti-adm.Info
- Publication number
- MX2024010899A MX2024010899A MX2024010899A MX2024010899A MX2024010899A MX 2024010899 A MX2024010899 A MX 2024010899A MX 2024010899 A MX2024010899 A MX 2024010899A MX 2024010899 A MX2024010899 A MX 2024010899A MX 2024010899 A MX2024010899 A MX 2024010899A
- Authority
- MX
- Mexico
- Prior art keywords
- adm
- antibody
- adrenomedulin
- stable aqueous
- aqueous formulation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22162271 | 2022-03-15 | ||
| PCT/EP2023/056663 WO2023175035A1 (en) | 2022-03-15 | 2023-03-15 | Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024010899A true MX2024010899A (es) | 2024-12-06 |
Family
ID=80780591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024010899A MX2024010899A (es) | 2022-03-15 | 2024-09-05 | Formulación acuosa estable de un anticuerpo anti-adrenomedulina (adm) o fragmento de anticuerpo anti-adm. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250304671A1 (enExample) |
| EP (1) | EP4493588A1 (enExample) |
| JP (1) | JP2025509304A (enExample) |
| CN (1) | CN119072492A (enExample) |
| AU (1) | AU2023233838A1 (enExample) |
| CA (1) | CA3254142A1 (enExample) |
| IL (1) | IL315632A (enExample) |
| MX (1) | MX2024010899A (enExample) |
| WO (1) | WO2023175035A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025056807A1 (en) * | 2023-09-15 | 2025-03-20 | Basf Se | Stabilized biopolymer composition, their manufacture and use |
| WO2025133235A1 (en) * | 2023-12-22 | 2025-06-26 | Pam Theragnostics Gmbh | Adm-gly as marker for early predicting sepsis |
| WO2026046978A1 (en) * | 2024-08-26 | 2026-03-05 | Pam Theragnostics Gmbh | Anti-adm antibodies, anti-adm antibody fragment or anti-adm non-ig scaffold for therapy or prevention of immune effector cell therapy side effects |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| AU2002213441B2 (en) * | 2000-10-12 | 2006-10-26 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| AU2002323501C1 (en) | 2001-08-30 | 2010-04-29 | Biorexis Technology, Inc | Modified transferrin fusion proteins |
| EP1620734A1 (en) | 2003-04-25 | 2006-02-01 | Genova Ltd. | Secreted polypeptide species reduced cardiovascular disorders |
| US20050164301A1 (en) | 2003-10-24 | 2005-07-28 | Avidia Research Institute | LDL receptor class A and EGF domain monomers and multimers |
| US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
| US20070280886A1 (en) | 2004-09-09 | 2007-12-06 | Bayer Healthcare Ag | Diagnostics and Therapeutics for Diseases Associated with Adrenomedullin Receptor (Amdr) |
| AU2005287557B2 (en) | 2004-09-21 | 2011-10-13 | Biontech Ag | Use of microproteins as tryptase inhibitors |
| ES2373832T3 (es) | 2007-12-19 | 2012-02-09 | Affibody Ab | Polipéptido derivado de proteína a y capaz de unirse a pdgf. |
| BRPI0921469B1 (pt) | 2008-11-03 | 2022-01-18 | Molecular Partners Ag | Proteínas de ligação que inibem a interação com o receptor de vegf-a, composição farmacêutica |
| MX2012002428A (es) | 2009-08-27 | 2012-09-12 | Covagen Ag | Compuestos de union il-17 y usos medicos de los mismos. |
| RU2553333C2 (ru) | 2009-12-14 | 2015-06-10 | Сцил Протеинс Гмбх | Способ идентификации гетеромультимерных модифицированных убиквитиновых белков со способностью связываться с лигандами |
| PL2580236T3 (pl) | 2010-06-08 | 2019-09-30 | Pieris Pharmaceuticals Gmbh | Muteiny lipokaliny łez wiążące IL-4 R alfa |
| ES2494190T3 (es) | 2011-11-16 | 2014-09-15 | Adrenomed Ag | Anticuerpo anti-adrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o andamiaje proteico sin Ig anti-ADM para reducir el riesgo de mortalidad en un paciente que padece una enfermedad crónica o aguda o un estado agudo |
| IL283215B2 (en) | 2011-11-16 | 2024-05-01 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment and pharmaceutical compostions comprising the same |
| LT3553084T (lt) | 2011-11-16 | 2023-03-10 | Adrenomed Ag | Anti-adrenomedulino (adm) antikūnas arba anti-adm antikūno fragmentas, arba anti-adm ne-ig karkasas, skirtas organų funkcijos sutrikimo arba organų nepakankamumo profilaktikai arba sumažinimui paciento, sergančio lėtine arba ūmine liga arba esančio ūminės būklės, organizme |
| EP2780370B1 (en) | 2011-11-16 | 2019-09-25 | AdrenoMed AG | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation |
| PT2780371T (pt) | 2011-11-16 | 2019-01-30 | Adrenomed Ag | Anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou uma estrutura não ig anti-adm para a regulação do equilíbrio de fluidos num doente com uma doença aguda ou crónica |
| DE112017002105T5 (de) | 2016-04-21 | 2019-04-25 | Sphingotec Therapeutics Gmbh | Verfahren zur Bestimmung von DPP3 und therapeutische Verfahren |
| JP7727371B2 (ja) | 2016-12-16 | 2025-08-21 | アドレノメト アクチェンゲゼルシャフト | うっ血の処置と治療を必要とする患者でその処置と治療に使用するための抗アドレノメデュリン（ＡＤＭ）抗体、または抗ＡＤＭ抗体フラグメント、または抗ＡＤＭ非Ｉｇ足場 |
| WO2019077082A1 (en) * | 2017-10-18 | 2019-04-25 | Adrenomed Ag | SURVEILLANCE OF THERAPY UNDER TREATMENT WITH ANTI-ADRENOMEDULIN BINDER (ADM) |
| CN115244080A (zh) * | 2020-02-27 | 2022-10-25 | 艾德里诺医药公司 | 用于治疗或预防休克的抗肾上腺髓质素(ADM)抗体或抗ADM抗体片段或抗ADM非Ig支架 |
-
2023
- 2023-03-15 CA CA3254142A patent/CA3254142A1/en active Pending
- 2023-03-15 CN CN202380036069.7A patent/CN119072492A/zh active Pending
- 2023-03-15 AU AU2023233838A patent/AU2023233838A1/en active Pending
- 2023-03-15 EP EP23711082.0A patent/EP4493588A1/en active Pending
- 2023-03-15 IL IL315632A patent/IL315632A/en unknown
- 2023-03-15 JP JP2024553456A patent/JP2025509304A/ja active Pending
- 2023-03-15 US US18/844,746 patent/US20250304671A1/en active Pending
- 2023-03-15 WO PCT/EP2023/056663 patent/WO2023175035A1/en not_active Ceased
-
2024
- 2024-09-05 MX MX2024010899A patent/MX2024010899A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL315632A (en) | 2024-11-01 |
| CA3254142A1 (en) | 2023-09-21 |
| AU2023233838A1 (en) | 2024-09-26 |
| JP2025509304A (ja) | 2025-04-11 |
| WO2023175035A1 (en) | 2023-09-21 |
| EP4493588A1 (en) | 2025-01-22 |
| US20250304671A1 (en) | 2025-10-02 |
| CN119072492A (zh) | 2024-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024010899A (es) | Formulación acuosa estable de un anticuerpo anti-adrenomedulina (adm) o fragmento de anticuerpo anti-adm. | |
| WO2019171253A8 (en) | Anti-pd-1 antibody compositions | |
| MX2025010757A (es) | Formulacion farmaceutica de ph bajo | |
| CU20190015A7 (es) | Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad y composiciones farmacéuticas que las comprenden | |
| CL2019002250A1 (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco. (divisional solicitud 201803520) | |
| EP4650371A3 (en) | Antibody-containing preparation | |
| NZ719036A (en) | Anti-pdl1 antibody formulations | |
| CY1122181T1 (el) | Φαρμακοτεχνικη μορφη αντισωματος | |
| EA201991701A1 (ru) | Состав на основе моноклонального антитела к rsv | |
| CO2017007693A2 (es) | Formulación acuosa estable de anticuerpo anti-factor de crecimiento celular endotelial vascular (vegf) | |
| CO2021010697A2 (es) | Formulación de anticuerpos terapéuticos | |
| AR092401A1 (es) | Formulaciones de anticuerpos anti-receptor de prolactina (anti-prlr) | |
| CO6251275A2 (es) | Formulaciones de inmunoglobulina liofilizadas y metodos para su preparacion | |
| CO2020013571A2 (es) | Formulaciones estables de anticuerpos terapéuticos | |
| IL274897B2 (en) | Formulations of dengue virus vaccine compositions | |
| EA202192405A1 (ru) | Составы антител против il-36r | |
| SA521421715B1 (ar) | تركيبات سيماجلوتيد ثابتة واستخداماتها | |
| MX2021015298A (es) | Anticuerpo anti-epha4 humano. | |
| BR112021019959A2 (pt) | Anticorpo biespecífico, e, formulação farmacêutica | |
| MX2021007393A (es) | Formulacion de solucion de proteinas que contiene una alta concentracion de un anticuerpo anti-vegf. | |
| AR097840A1 (es) | Una formulación de un conjugado de la hormona de crecimiento humana de la actividad prolongada, procedimiento, kit | |
| AR115365A1 (es) | Formulaciones de anticuerpos anti-pd-l1 humanos | |
| MX2023001160A (es) | Composicion farmaceutica del anticuerpo anti-pd-1 y uso del mismo. | |
| CO2022005737A2 (es) | Formulación estable de anticuerpo de integrina | |
| CL2023000491A1 (es) | Composiciones de erenumab y usos de las mismas (divisional de solicitud n° 02519-2020). |